Immunoprofilaktyka chorób zakaźnych układu oddechowego koni - aktualny stan wiedzy

• Autorzy: Kalinowski M. , Gradzki Z. , Jarosz L.

Warianty tytułu

EN

Immunoprophylaxis of respiratory tract diseases in horses: the current state of knowledge

• Języki publikacji: PL

Abstrakty

EN

Respiratory tract diseases are distributed in the horse population world-wide and used to be a significant clinical, epidemiological and therapeutic problem in studs, training stables and small farms. Respiratory tract infections occur in horses of all ages regardless of their type of utility. The main role in the aetiology of respiratory tract infections in horses is played by viruses, with the most important being influenza viruses (EIV) and herpesviruses (EHV1 and EHV4). Less important from the clinical and epidemiological point of view is the Equine Arteritis Virus (EAV). Besides viral diseases, bacterial respiratory tract infections, mainly strangles and rhodococcosis, are also an important problem in the horse breeding industry. Control of respiratory tract diseases in horses should be based on a complex procedure including antibiotic therapy, enhancement of the non-specific immunity, devastation of pathogens in the environment, and farm management. The most important procedures, especially concerning viral diseases, are preventive measures achieved by specific prophylaxis. Systematic vaccinations lead to the stimulation of the equine immune system with the generation of protective immunity against infections or reduction their clinical consequences. This paper presents the current state of knowledge on the immunoprophylaxis of the most important respiratory tract infections of horses, with special attention to the vaccinations, with the use of products officially approved in Poland and the EU.

Słowa kluczowe

PL

konie; choroby zwierzat; choroby ukladu oddechowego; choroby zakazne; immunoprofilaktyka; szczepienia ochronne; wirusowe zapalenie tetnic koni; influenza koni; zolzy; rodokokoza; herpeswirusy; infekcja wirusowa

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2015
• Tom: 71
• Numer: 02
• Opis fizyczny: s.75-83,tab.,bibliogr.

Twórcy

autor

Kalinowski M.

• Katedra Epizootiologii i Klinika Chorób Zakaźnych, Wydział Medycyny Weterynaryjnej, Uniwersytet Przyrodniczy w Lublinie, ul.Głęboka 30, 20-612 Lublin

autor

Gradzki Z.

• Katedra Epizootiologii i Klinika Chorób Zakaźnych, Wydział Medycyny Weterynaryjnej, Uniwersytet Przyrodniczy w Lublinie, ul.Głęboka 30, 20-612 Lublin

autor

Jarosz L.

• Katedra Epizootiologii i Klinika Chorób Zakaźnych, Wydział Medycyny Weterynaryjnej, Uniwersytet Przyrodniczy w Lublinie, ul.Głęboka 30, 20-612 Lublin

Bibliografia

• Ault A., Zajac A. M., Kong W. P., Gorres J. P., Royals M., Wei C. J., Bao S., Yang Z. Y., Reedy S. E., Sturgill T. L., Page A. E., Donofrio-Newman J., Adams A. A., Balasuriya U. B., Horohov D. W., Chambers T. M., Nabel G. J., Rao S. S.: Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies. Vaccine 2012, 30, 3965-3974.
• Balasuriya U. B., Go Y. Y., Maclachlan N. J.: Equine arteritis virus. Vet. Microbiol. 2013, in press.
• Balasuriya U. B., Heidner H. W., Davis N. L., Wagner H. M., Hullinger P. J.,Hedges J. F.: Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses. Vaccine 2002, 20, 1609-1617.
• Balasuriya U. B., Heidner H. W., Hedges J. F., Williams J. C., Davis N. L., Johnston R. E.: Expression of two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles. J. Virol. 2000, 74, 10623-10630.
• Balasuriya U. B., Maclachlan N. J.: The immune response to equine arteritis virus: potential lessons for other arteriviruses. Vet. Immunol. Immunopathol. 2004, 102, 107-129.
• Balasuriya U. B., MacLachlan N. J.: Equine viral arteritis, [w:] Sellon D. C., Long M. T. (ed.): Equine Infectious Diseases. Saunders Elsevier, St. Louis 2007, s. 153-164.
• Balasuriya U. B., Snijder E. J., Heidner H. W., Zhang J., Zevenhoven-Dobbe J. C., Boone J. D., McCollum W. H., Timoney P. J., MacLachlan N. J.: Development and characterization of an infectious cDNA clone of the virulent Bucyrus strain of Equine arteritis virus. J. Gen. Virol. 2007, 88, 918-924.
• Barnier Quer C., Elsharkawy A., Romeijn S., Kros A., Jiskoot W.: Cationic liposomes as adjuvants for influenza hemagglutinin: more than charge alone. Eur. J. Pharm. Biopharm. 2012, 81, 294-302.
• Breathnach C. C., Yeargan M. R., Sheoran A. S., Allen G. P.: The mucosal humoral immune response of the horse to infective challenge and vaccination with equine herpesvirus-1 antigens. Equine Vet. J. 2001, 33, 651-657.
• Bresgen C., Lämmer M., Wagner B., Osterrieder N., Damiani A. M.: Serological responses and clinical outcome after vaccination of mares and foals with equine herpesvirus type 1 and 4 (EHV-1 and EHV-4) vaccines. Vet. Microbiol. 2012, 160, 9-16.
• Bryant N. A., Paillot R., Rash A. S., Medcalf E., Montesso F., Ross J., Watson J., Jeggo M., Lewis N. S., Newton J. R., Elton D. M.: Comparison of two modern vaccines and previous influenza infection against challenge with an equine influenza virus from the Australian 2007 outbreak. Vet. Res. 2010, 41, 19.
• Bryant N. A., Rash A. S., Russell C. A., Ross J., Cooke A., Bowman S.: Antigenic and genetic variations in European and North American equine influenza virus strains (H3N8) isolated from 2006 to 2007. Vet. Microbiol. 2009, 138, 41-52.
• Castillo-Olivares J., Wieringa R., Bakonyi T., Vries A. A. de, Davis-Poynter N. J., Rottier P. J.: Generation of a candidate live marker vaccine for equine arteritis virus by deletion of the major virus neutralization domain. J. Virol. 2003, 77, 8470-8480.
• Cauchard J., Sevin C., Ballet J. J., Taouji S.: Foal IgG and opsonizing anti-Rhodococcus equi antibodies after immunization of pregnant mares with a protective VapA candidate vaccine. Vet. Microbiol. 2004, 104, 73-81.
• Chambers T. M., Holland R. E., Tudor L. R., Townsend H. G., Cook A., Bogdan J., Lunn D. P., Hussey S., Whitaker-Dowling P., Youngner J. S., Sebring R. W., Penner S. J., Stiegler G. L.: A new modified live equine influenza virus vaccine: phenotypic stability, restricted spread and efficacy against heterologous virus challenge. Equine Vet. J. 2001, 33, 630-636.
• Cullinane A., Newton J. R.: Equine influenza-A global perspective. Vet. Microbiol. 2013, in press.
• Daly J. M., Lai A. C., Binns M. M., Chambers T. M., Barrandeguy M., Mumford J. A.: Antigenic and genetic evolution of equine H3N8 influenza A viruses. J. Gen. Virol. 1996, 77, 661-671.
• Elton D., Bryant N.: HBLB’s advances in equine veterinary science and practice Facing the threat of equine influenza. Equine Vet. J. 2011, 43, 250-258.
• Equine influenza. Conclusions and Recommendations. OIE Expert Surveillance Panel on Equine Influenza Vaccine Composition, OIE Headquarters, 4 March 2013. http://www.oie.int/our-scientific-expertise/specific-information-and-recommendations/equine-influenza.
• Firth A. E., Zevenhoven-Dobbe J. C., Wills N. M., Go Y. Y., Balasuriya U. B., Atkins J. F., Snijder E. J., Posthuma C. C.: Discovery of a small arterivirus gene that overlaps the GP5 coding sequence and is important for virus production. J. Gen. Virol. 2011, 92, 1097-1106.
• Flock M., Jacobsson K., Frykberg L., Hirst T. R., Franklin A., Guss B., Flock J. I.: Recombinant Streptococcus equi proteins protect mice in challenge experiments and induce immune response in horses. Infect. Immun. 2004, 72, 3228-3236.
• Flock M., Karlstrom A., Lannergard J., Guss B., Flock J. I.: Protective effect of vaccination with recombinant proteins from Streptococcus equi subspecies equi in a strangles model in the mouse. Vaccine 2006, 24, 4144-4152.
• Fukunaga Y., Wada R., Hirasawa K., Kamada M., Kunanomido T., Akiyama Y.: Effect of the modified Bucyrus strain of equine arteritis virus experimentally inoculated into horses. Bull. Equine Res. Inst. 1982, 19, 97-101.
• Giguere S., Cohen N. D., Keith Chaffin M., Hines S. A., Hondalus M. K., Prescott J. F., Slovis N. M.: Rhodococcus equi: Clinical Manifestations, Virulence, and Immunity. J. Vet. Intern. Med. 2011, 25, 1221-1230.
• Giguère S., Gaskin J. M., Miller C., Bowman J. L.: Evaluation of a commercially available hyperimmune plasma product for prevention of naturally acquired pneumonia caused by Rhodococcus equi in foals. J. Am. Vet. Med. Assoc. 2002, 220, 59-63.
• Goehring L. S., Wagner B., Bigbie R., Hussey S. B., Rao S., Morley P. S., Lunn D. P.: Control of EHV-1 viremia and nasal shedding by commercial vaccines. Vaccine 2010, 28, 5203-5211.
• Grądzki Z., Zietek-Barszcz A.: Detection of Rhodococcus equi in tracheobronchial aspirate of foals in enzootic farms depending on age and season. Bull. Vet. Inst. Pulawy 2011, 55, 619-624.
• Guss B., Flock M., Frykberg L., Waller A. S., Robinson C., Smith K. C., Flock J. I.: Getting to grips with strangles: an effective multi-component recombinant vaccine for the protection of horses from Streptococcus equi infection. PLoS Pathog. 2009, 5, e1000584.
• Hannant D., Jessett D., O’Neill T., Dolby C. A., Cook R. F., Mumford J. A.: Responses of ponies to equid herpesvirus-1 ISCOM vaccination and challenge with virus to the homologous strain. Res. Vet. Sci. 1993, 54, 299-305.
• Heldens J. G. M., Hannant D., Cullinane A. A., Prendergast M. J., Mumford J. A., Nelly M., Kydd J. H., Weststrate M. W., Hoven R. Van Den: Clinical and virological evaluation of the efficacy of an inactivated EHV-1 and EHV-4 whole virus vaccine (Duvaxyn EHV1,4). Vaccination/challenge experiments in foals and pregnant mares. Vaccine 2001, 19, 4307-4317.
• Hines M. T.: Rhodococcus equi, [w:] Sellon D. C., Long M. T. (ed.): Equine Infectious Diseases. Saunders Elsevier, St. Louis 2007, s. 281-295.
• Hooper-McGrevy K. E., Wilkie B. N., Prescott J. F.: Virulence-associated protein-specific serum immunoglobulin G-isotype expression in young foals protected against Rhodococcus equi pneumonia by oral immunization with virulent R. equi. Vaccine 2005, 23, 5760-5767.
• Horspool L. J., King A.: Equine influenza vaccines in Europe: A view from the animal health industry. Equine Vet. J. 2013, 45, 774-775.
• Jacobs A. A., Goovaerts D., Nuijten P. J., Theelen R. P., Hartford O. M., Foster T. J.: Investigations towards an efficacious and safe strangles vaccine: submucosal vaccination with a live attenuated Streptococcus equi. Vet. Rec. 2000, 147, 563-567.
• Kydd J. H., Townsend H. G., Hannant D.: The equine immune response to equine herpesvirus-1: the virus and its vaccines. Vet. Immunol. Immunopathol. 2006, 111, 15-30.
• Landolt G. A., Townsend H. G., Lunn D. P.: Equine influenza infection, [w:] Sellon D. C., Long M. T. (ed.): Equine Infectious Diseases. Saunders Elsevier, St. Louis 2007, s. 124-134.
• Li Y., Wang Z., Chen J., Ernst R. K., Wang X.: Influence of lipid A acylation pattern on membrane permeability and innate immune stimulation. Mar. Drugs. 2013, 11, 3197-3208.
• Maanen C. van, Cullinane A.: Equine influenza virus infections: an update. Vet. Q. 2002 24, 79-94.
• MacLachlan N. J., Balasuriya U. B., Davis N. L., Collier M., Johnston R. E., Ferraro G. L., Guthrie A. J.: Experiences with new generation vaccines against equine viral arteritis, West Nile disease and African horse sickness. Vaccine 2007, 25, 5577-5582.
• Minke J. M., Audonnet J. C., Fischer L.: Equine viral vaccines: the past, present and future. Vet. Res. 2004, 35, 425-443.
• Minke J. M., Fischer L., Baudu P., Guigal P. M., Sindle T., Mumford J. A., Audonnet J. C.: Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination. Vet. Immunol. Immunopathol. 2006, 111, 47-57.
• Mumford J. A., Wood J.: Establishing an acceptable threshold for equine influenza vaccines. Dev. Biol. Stand. 1992, 79, 137-146.
• Muscatello G.: Rhodococcus equi pneumonia in the foal – part 2: diagnostics, treatment and disease management. Vet. J. 2012, 192, 27-33.
• Oliveira A. F., Ferraz L. C., Brocchi M., Roque-Barreira M. C.: Oral administration of a live attenuated Salmonella vaccine strain expressing the VapA protein induces protection against infection by Rhodococcus equi. Microbes Infect. 2007, 9, 382-390.
• Oliveira A. F., Ruas L. P., Cardoso S. A., Soares S. G., Roque-Barreira M. C.: Vaccination of mice with salmonella expressing VapA: mucosal and systemic Th1 responses provide protection against Rhodococcus equi infection. PLoS One 2010, 5, e8644.
• Paillot R., Hannant D., Kydd J. H., Daly J. M.: Vaccination against equine influenza: Quid novi? Vaccine 2006, 24, 4047-4061.
• Paillot R., Kydd J. H., Sindle T., Hannant D., Edlund Toulemonde C., Audonnet J. C., Minke J. M., Daly J. M.: Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus. Vet. Immunol. Immunopathol. 2006, 112, 225-233.
• Paillot R., Prowse L.: ISCOM-matrix-based equine influenza (EIV) vaccine stimulates cell-mediated immunity in the horse. Vet. Immunol. Immunopathol. 2012, 145, 516-521.
• Patel J. R., Heldens J.: Equine herpesviruses 1 (EHV-1) and 4 (EHV-4) – epidemiology, disease and immunoprophylaxis: A brief review. Vet. J. 2005, 170, 14-23.
• Pusterla N., Hussey S. B., Mapes S., Johnson C., Collier J. R., Hill J., Lunn D. P., Wilson W. D.: Molecular investigation of the viral kinetics of equine herpesvirus-1 in blood and nasal secretions of horses after corticosteroid-induced recrudescence of latent infection. J. Vet. Intern. Med. 2010, 24, 1153-1157.
• Rush B., Mair T. (ed.): Equine respiratory diseases. Blackwell Science Ltd, Oxford 2004, p. xvii.
• Sellon D. C., Sweeney C. R., Timoney P. J., Newton J. R., Hines M. T.: Streptococcal infections, [w:] Sellon D. C., Long M. T. (ed.): Equine Infectious Diseases. Saunders Elsevier, St. Louis 2007, s. 244-257.
• Sheoran A. S., Artiushin S., Timoney J. F.: Nasal mucosal immunogenicity for the horse of a SeM peptide of Streptococcus equi genetically coupled to cholera toxin. Vaccine 2002, 20, 1653-1659.
• Slater J. D.: Equine herpesviruses, [w:] Sellon D. C., Long M. T. (ed.): Equine Infectious Diseases. Saunders Elsevier, St. Louis 2007, s. 134-153.
• Takai S.: Epidemiology of Rhodococcus equi infections: a review. Vet. Microbiol. 1997, 56, 167-176.
• Takai S., Ohbushi S., Koike K., Tsubaki S., Oishi H., Kamada M.: Prevalence of virulent Rhodococcus equi in isolates from soil and feces of horses from horse-breeding farms with and without endemic infections. J. Clin. Microbiol. 1991, 29, 2887-2889.
• Thomson G. R., Mumford J. A., Smith I. M.: Experimental immunization against respiratory disease due to equine herpesvirus 1 infection (rhinopneumonitis) using formalin-inactivated virus with various adjuvants. Vet. Microbiol. 1979, 4, 209-222.
• Thormanna N., Walleb G. R. Van de, Azaba W., Osterriedera N.: The role of secreted glycoprotein G of equine herpesvirus type 1 and type 4 (EHV-1 and EHV-4) in immune modulation and virulence. Virus Res. 2012, 169, 203-211.
• Varga J., Fodor L., Rusvai M., Soos I., Makrai L.: Prevention of Rhodococcus equi pneumonia of foals using two different inactivated vaccines. Vet. Microbiol. 1997, 56, 205-210.
• Waddell G. H., Teigland M. B., Sigel M. M.: A new influenza virus associated with equine respiratory disease. J. Am. Vet. Med. Assoc. 1963, 143, 587-590.
• Waller A. S.: Strangles: Taking steps towards eradication. Vet. Microbiol. 2013, in press.
• Waller A. S., Keith A. J.: Getting a grip on strangles: recent progress towards improved diagnostics and vaccines. Vet. J. 2007, 173, 492-501.
• Wilson W. D., Pusterla N.: Immunoprophylaxis, [w:] Sellon D. C., Long M. T. (ed.): Equine Infectious Diseases. Saunders Elsevier, St. Louis 2007, s. 556-577.
• Woodland R. M.: Influenza vaccine strains: Licensing perspectives. Equine Vet. J. 2013, 45, 772-773.
• Zhang J., Go Y. Y., Huang C. M., Meade B. J., Lu Z., Snijder E. J., Timoney P. J., Balasuriya U. B.: Development and characterization of an infectious cDNA clone of the modified live virus vaccine strain of equine arteritis virus. Clin. Vaccine Immunol. 2012, 19, 1312-1321.